The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
Open accessAbstract
BACKGROUND: The aromatase inhibitor letrozole is a more effective treatment for metastatic breast cancer and more effective in the neoadjuvant setting than tamoxifen. We compared letrozole with tamoxifen as adjuvant treatment for steroid-hormone-receptor-positive breast cancer in postmenopausal women. METHODS: The Breast International Group (BIG) 1-98 study is a randomized, phase 3, double-blind trial that compared five years of treatment with various adjuvant endocrine therapy regimens in postmenopausal women with hormone-receptor-positive breast cancer: letrozole, letrozole followed by tamoxifen, tamoxifen, and tamoxifen followed by letrozole. This analysis compares the two groups assigned to receive letrozole initially with the two groups assigned to receive tamoxifen initially; events and follow-up in the sequential-treatment groups were included up to the time that treatments were switched. RESULTS: A total of 8010 women with data that could be assessed were enrolled, 4003 in the letrozole group and 4007 in the tamoxifen group. After a median follow-up of 25.8 months, 351 events had occurred in the letrozole group and 428 events in the tamoxifen group, with five-year disease-free survival estimates of 84.0 percent and 81.4 percent, respectively. As compared with tamoxifen, letrozole significantly reduced the risk of an event ending a period of disease-free survival (hazard ratio, 0.81; 95 percent confidence interval, 0.70 to 0.93; P=0.003), especially the risk of distant recurrence (hazard ratio, 0.73; 95 percent confidence interval, 0.60 to 0.88; P=0.001). Thromboembolism, endometrial cancer, and vaginal bleeding were more common in the tamoxifen group. Women given letrozole had a higher incidence of skeletal and cardiac events and of hypercholesterolemia. CONCLUSIONS: In postmenopausal women with endocrine-responsive breast cancer, adjuvant treatment with letrozole, as compared with tamoxifen, reduced the risk of recurrent disease, especially at distant sites. (ClinicalTrials.gov number, NCT00004205.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi326 · Cited by 1,127
A Survey of Exact Inference for Contingency Tables
Agresti, A. (1992) · Statistical Science · doi:10.1214/ss/1177011454 · Cited by 1,097
Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3808 · Cited by 1,060
Winer, E. P., Hudis, C., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R., Edge, S. B., Gralow, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.121 · Cited by 1,031
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jänicke, F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2596 · Cited by 1,015
Overview of the main outcomes in breast-cancer prevention trials
Cuzick, J., Powles, T., Veronesi, U., Forbes, J., Edwards, R., Ashley, S., & Boyle, P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12342-2 · Cited by 965
Aromatase Inhibitors in Breast Cancer
Smith, I. E., & Dowsett, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023246 · Cited by 905
The ATAC (Arimidex, T. A. O. I. C. T. G. (2003) · Cancer · doi:10.1002/cncr.11745 · Cited by 861
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jaenicke, F., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.194 · Cited by 746
Veronesi, U., Boyle, P., Goldhirsch, A., Orecchia, R., & Viale, G. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66546-4 · Cited by 542
Howell, A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)74803-0 · Cited by 398
Meta-analysis of vascular and neoplastic events associated with tamoxifen
Braithwaite, R. S., Chlebowski, R. T., Lau, J., George, S., Hess, R., & Col, N. F. (2003) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2003.20724.x · Cited by 338
Geisler, J., King, N., Dowsett, M., Ottestad, L., Lundgren, S., Walton, P., Kormeset, P., & Lønning, P. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.531 · Cited by 336
Rutqvist, L. E., & Anders Mattsson for the Stockholm Breast Cancer Study Group (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.17.1398 · Cited by 334
Geisler, J., King, N. C., Anker, G. B., Ornati, G., di Salle, E., Lønning, P. E., & Dowsett, M. (1998) · PubMed · Cited by 314
McDonald, C. C., Alexander, F. E., Whyte, B. W., Forrest, A. P., & Stewart, H. J. (1995) · BMJ · doi:10.1136/bmj.311.7011.977 · Cited by 276
Dowsett, M., Cuzick, J., Wale, C., Howell, T., Houghton, J., & Baum, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.4829 · Cited by 260
Dowsett, M., Jones, A. L., Johnston, S. R. D., Jacobs, S., Trunet, P. F., & Smith, I. E. (1995) · PubMed · Cited by 238
Wasan, K. M., Goss, P. E., Pritchard, P. H., Shepherd, L., Palmer, M. J., Liu, S., Tu, D., Ingle, J. N., Heath, M., DeAngelis, D., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi158 · Cited by 179
Effect of letrozole on the lipid profile in postmenopausal women with breast cancer
Elisaf, M., Bairaktari, E. T., Nicolaides, C., Kakaidi, B., Tzallas, C., Katsaraki, A., & Pavlidis, N. A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00155-1 · Cited by 150
Reís, S. E., Costantino, J. P., Wickerham, D. L., Tan-Chiu, E., Wang, J., & Kavanah, M. T. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.1.16 · Cited by 146
Chang, J. C., Powles, T. J., Ashley, S. E., Gregory, R. K., Tidy, V. A., Treleaven, J. G., & Singh, R. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010715 · Cited by 116
Aromatase inhibitors in breast cancer.
Lønning, P. E. (2004) · Endocrine Related Cancer · doi:10.1677/erc.0.0110179 · Cited by 115
Bradbury, B. D., Lash, T. L., Kaye, J. A., & Jick, S. S. (2005) · Cancer · doi:10.1002/cncr.20900 · Cited by 68
Research works printed but not linked: 5
- Dowsett M, 1995, Clin Cancer Res, 1, 1511
- Geisler J, 1998, Clin Cancer Res, 4, 2089
- Mantel N, 1966, Cancer Chemother Rep, 50, 163
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- 10.1016/S1049-3867(01)00075-5 · doi:10.1016/s1049-3867(01)00075-5
Cited by
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Prevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Kahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
Metadata
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-12-29
- Volume
- 353
- Issue
- 26
- Pages
- 2747-2757
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1531964529
- Cited by
- 1,577
- References
- 36
- FWCI
- 52.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.